BIOMAT Database Logo BIOMAT Database Logo

Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602. 1977

G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010648 Phenylacetates Derivatives of phenylacetic acid. Included under this heading are a variety of acid forms, salts, esters, and amides that contain the benzeneacetic acid structure. Note that this class of compounds should not be confused with derivatives of phenyl acetate, which contain the PHENOL ester of ACETIC ACID. Benzeneacetates,Benzeneacetic Acids,Phenylacetic Acids,Acids, Benzeneacetic,Acids, Phenylacetic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006719 Homovanillic Acid A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid. 3-Methoxy-4-Hydroxyphenylacetic Acid,4-Hydroxy-3-Methoxyphenylacetic Acid,3 Methoxy 4 Hydroxyphenylacetic Acid,4 Hydroxy 3 Methoxyphenylacetic Acid,Acid, 3-Methoxy-4-Hydroxyphenylacetic,Acid, 4-Hydroxy-3-Methoxyphenylacetic,Acid, Homovanillic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide

Related Publications

G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi
CSF HVA and 5-HIAA.
June 1979, Neurology,
G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi
Mental symptoms in Parkinsonian patients treated with L-dopa.
July 1970, Lancet (London, England),
G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi
Mental symptoms in parkinsonian patients treated with L-dopa.
October 1970, Lancet (London, England),
G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi
5-HIAA and HVA in CSF in patients with idiopathic pain disorders.
April 1987, Biological psychiatry,
G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi
[Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
January 1972, Revue canadienne de biologie,
G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi
[L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
November 1972, Nederlands tijdschrift voor geneeskunde,
G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi
A clinico-biochemical correlation in a Parkinsonian patient treated with levodopa and decarboxylase inhibitor (Ro 4-4602). A model study.
September 1972, Journal of the neurological sciences,
G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi
Determination of HVA and 5-HIAA in ventricular CSF of patients with brain tumors.
January 1974, Journal of neurosurgical sciences,
G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi
[Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
January 1972, Schweizerische medizinische Wochenschrift,
G Campanella, and S Algeri, and C Cerletti, and E Dolfini, and A Jori, and F Rinaldi
[Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
October 1971, Wiener medizinische Wochenschrift (1946),
Copied contents to your clipboard!